INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013 ongoing_tax_audit	Dec. 31, 2012
Current income tax expense
Federal	$ (23,000)	$ 30,000
State	0	9,000
Canada	0	0
Total current tax expense (benefit)	(23,000)	39,000
Deferred tax asset
Tangible and intangible depreciable assets	874,000	853,000
Manufactured drug product inventory to be used in research	1,459,000	757,000
Provisions	93,000	30,000
Financing fees	445,000	628,000
Net operating loss carry forwards	13,099,000	6,883,000
Scientific research and experimental development expenditures	5,766,000	4,245,000
Deferred tax assets	21,736,000	13,396,000
Valuation allowance	(21,736,000)	(13,396,000)
Net deferred tax assets	0	0
Additional disclosures
Amount of increase in valuation allowance	8,300,000
Share issue expenses not deducted	1,700,000	2,400,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions
Unrecognized tax benefits that would not impact effective tax rate	200,000	200,000
Accrual for interest or penalties on tax matters	0	0
Number of ongoing tax audits	0
Canadian Federal
Additional disclosures
Scientific research and experimental development expenses deductible for income tax purposes	20,700,000	15,200,000
Net operating loss carry forwards (NOLs)	44,054,000	25,300,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions
Unrecognized tax positions, beginning of year	159,000	157,000
Gross decrease — current period tax positions	0	0
Gross increase — current period tax positions	0	2,000
Gross decrease — prior period tax positions	(48,000)	0
Gross increase — prior period tax positions	18,000	0
Unrecognized tax positions, end of year	129,000	159,000
Canadian Federal | 2030
Additional disclosures
Net operating loss carry forwards (NOLs)	5,907,000
Canadian Federal | 2031
Additional disclosures
Net operating loss carry forwards (NOLs)	7,059,000
Canadian Federal | 2032
Additional disclosures
Net operating loss carry forwards (NOLs)	12,371,000
Canadian Federal | 2033
Additional disclosures
Net operating loss carry forwards (NOLs)	18,717,000
Canadian Provincial
Additional disclosures
Scientific research and experimental development expenses deductible for income tax purposes	22,400,000	16,800,000
Net operating loss carry forwards (NOLs)	45,012,000	25,600,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions
Unrecognized tax positions, beginning of year	5,000	3,000
Gross decrease — current period tax positions	0	0
Gross increase — current period tax positions	0	2,000
Gross decrease — prior period tax positions	0	0
Gross increase — prior period tax positions	18,000	0
Unrecognized tax positions, end of year	23,000	5,000
Canadian Provincial | 2030
Additional disclosures
Net operating loss carry forwards (NOLs)	5,984,000
Canadian Provincial | 2031
Additional disclosures
Net operating loss carry forwards (NOLs)	7,066,000
Canadian Provincial | 2032
Additional disclosures
Net operating loss carry forwards (NOLs)	12,495,000
Canadian Provincial | 2033
Additional disclosures
Net operating loss carry forwards (NOLs)	19,467,000
US Federal
Additional disclosures
Net operating loss carry forwards (NOLs)	2,838,000	0
US Federal | 2030
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US Federal | 2031
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US Federal | 2032
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US Federal | 2033
Additional disclosures
Net operating loss carry forwards (NOLs)	2,838,000
US State
Additional disclosures
Net operating loss carry forwards (NOLs)	2,919,000
US State | 2030
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US State | 2031
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US State | 2032
Additional disclosures
Net operating loss carry forwards (NOLs)	0
US State | 2033
Additional disclosures
Net operating loss carry forwards (NOLs)	$ 2,919,000